Serotonin syndrome induced by fluvoxamine and oxycodone

Annals of Pharmacotherapy

Volumn 40, Issue 1, 2006, Pages 155-157

  Karunatilake, Harindra ^a   Buckley, Nicholas A ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Oxycodone; Serotonin syndrome

Indexed keywords

ANALGESIC AGENT; DEXTROMETHORPHAN; FLUVOXAMINE; OPIATE DERIVATIVE; OXYCODONE; PETHIDINE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL;

AGED; ARTICLE; CASE REPORT; CLONUS; CONFUSION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEVER; HUMAN; HYPERREFLEXIA; MALE; MUSCLE HYPERTONIA; NARANJO PROBABILITY SCALE; NAUSEA; PRIORITY JOURNAL; RATING SCALE; SEROTONIN SYNDROME; SEROTONIN UPTAKE; SHIVERING; SYMPTOMATOLOGY; TACHYCARDIA;

AGED; ANALGESICS, OPIOID; DEPRESSION; DRUG INTERACTIONS; FEMALE; FLUVOXAMINE; HUMANS; OXYCODONE; PAIN; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 32344444262     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E671     Document Type: Article

References (18)

1. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998;12:482-91.
2. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.
3. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
4. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 2000;79:201-9.
5. Chan BS, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG. Serotonin syndrome resulting from drug interactions. Med J Aust 1998;169:523-5.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
7. Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. J Clin Pharmacol 2001;41:224-7.
8. Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB. Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Assoc 2005;6:265-9.
9. Grach M, Massalha W, Pud D, Adler R, Eisenberg E. Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol 2004;58:235-42.
10. Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274:1263-70.
11. Raffa RB. A novel approach to the pharmacology of analgesics. Am J Med 1996;101(suppl 1A):40S-6S.
12. Nielsen CK, Ross FB, Smith MT. Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J Pharmacol Exp Ther 2000;295:91-9.
13. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review, J Pain 2003;4:231-56.
14. Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. Drug Saf 1998;19:173-89.
15. Tao R, Ma Z, Auerbach SB, Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine. J Pharmacol Exp Ther 1998;286:481-8.
16. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37.
17. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64:603-11.
18. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z- doxepin in healthy volunteers. Pharmacogenetics 2002;12:571-80.